Back to News
Market Impact: 0.2
Basileas's Japan Partner Initiates Phase 2 Study Of Cresemba In Pediatric Deep Mycoses
Source: Nasdaq
Healthcare & Biotech
Basilea Pharmaceutica's Japanese partner, Asahi Kasei Therapeutics, has initiated a Phase 2 trial of antifungal drug Cresemba in Japanese pediatric patients at risk of deep mycoses. The trial expands Cresemba's clinical development into a pediatric indication in Japan, but the announcement provides no efficacy data or financial guidance.
AllMind Terminal
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request TrialMarket Sentiment
Overall Sentiment
mildly positive
Sentiment Score
0.30
Ticker Sentiment
BSLN0.50
More News
- Bausch Health raises 2026 outlook as third-quarter adjusted earnings surge 53%
- This hospice services stock is outperforming the S&P 500. Jefferies sees more gains ahead
- Waters’ new AI tool targets one of the pharmaceutical industry’s most tedious tasks
- Biotechs buck a sluggish IPO market, but investors should tread warily
- Wedbush cuts Geron stock price target to $5 on study halt
- Needham initiates Clover Health stock with buy on cohort economics